Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment of Francis Plat as chief medical officer. He is a cardiologist with extensive experience in cardio drug development.
Prior to this appointment he was vice president and therapeutic area head in atherosclerosis and cardiovascular at Merck Research Laboratories, and has previously worked at Daiichi-Sankyo, Novartis and Bristol-Myers Squibb. Dr Plat has been involved in developing, filing and repositioning many cardiovascular compounds including zintivity, brinavess and effient.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze